| 4.18 0.73 (21.16%) | 01-16 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 4.95 |
1-year : | 5.78 |
| Resists | First : | 4.23 |
Second : | 4.95 |
| Pivot price | 3.21 |
|||
| Supports | First : | 3.28 |
Second : | 2.7 |
| MAs | MA(5) : | 3.48 |
MA(20) : | 3.2 |
| MA(100) : | 3.32 |
MA(250) : | 3.06 |
|
| MACD | MACD : | 0 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 89.7 |
D(3) : | 75.1 |
| RSI | RSI(14): 65.5 |
|||
| 52-week | High : | 4.5 | Low : | 1.1 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ RPID ] has closed Bollinger Bands are 33.8% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 4.24 - 4.27 | 4.27 - 4.3 |
| Low: | 3.39 - 3.42 | 3.42 - 3.44 |
| Close: | 4.14 - 4.19 | 4.19 - 4.23 |
Rapid Micro Biosystems, Inc., a life sciences technology company, provides products for the detection of microbial contamination in the manufacture of pharmaceutical, medical devices, and personal care products in North America, Europe, and Asia. The company offers Growth Direct platform, which includes Growth Direct system, proprietary consumables, lab information management system connection software, and comprehensive customer support and validation services. Its platform automates and modernizes the manual microbial quality control (MQC) testing workflows for therapeutic modalities, such as biologics, vaccines, cell and gene therapies, and sterile injectables. The company also provides installation and verification, technical training, and support services. Its solutions are used in environmental monitoring, water testing, bioburden, and sterility release testing applications. The company was formerly known as Genomic Profiling Systems, Inc. and changed its name to Rapid Micro Biosystems, Inc. in January 2007. Rapid Micro Biosystems, Inc. was incorporated in 2006 and is headquartered in Lowell, Massachusetts.
Thu, 15 Jan 2026
RPID: Strong 2025 growth, expanding automation, and margin gains set up for continued success - TradingView — Track All Markets
Wed, 14 Jan 2026
Rapid Micro Biosystems reports 37% revenue growth in Q4 2025 By Investing.com - Investing.com Nigeria
Tue, 13 Jan 2026
Rapid Micro Biosystems Announces Record Preliminary Unaudited Fourth Quarter and Full Year 2025 Revenue - GlobeNewswire
Tue, 13 Jan 2026
190 automation systems now support faster, safer healthcare production - Stock Titan
Mon, 12 Jan 2026
Rapid Micro Biosystems Stock Hits 52-Week High at $3.18 - MSN
Wed, 07 Jan 2026
Rapid Micro Biosystems to Present at 44th Annual J.P. Morgan Healthcare Conference - Sahm
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 40 (M) |
| Shares Float | 20 (M) |
| Held by Insiders | 9.4 (%) |
| Held by Institutions | 58.6 (%) |
| Shares Short | 161 (K) |
| Shares Short P.Month | 301 (K) |
| EPS | -1 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1 |
| Profit Margin | -145.2 % |
| Operating Margin | -145.1 % |
| Return on Assets (ttm) | -29.9 % |
| Return on Equity (ttm) | -68.9 % |
| Qtrly Rev. Growth | 3 % |
| Gross Profit (p.s.) | 0.05 |
| Sales Per Share | 0.76 |
| EBITDA (p.s.) | -1.07 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -38 (M) |
| Levered Free Cash Flow | -23 (M) |
| PE Ratio | -4.18 |
| PEG Ratio | 0 |
| Price to Book value | 4.17 |
| Price to Sales | 5.45 |
| Price to Cash Flow | -4.42 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|